01 — At a Glance
The Comeback Nobody Believed In
- 52-Week High / Low₹1,610 / ₹610
- Q3 FY26 Revenue₹131 Cr
- Q3 FY26 PAT₹15.2 Cr
- TTM EPS₹14.01
- Annualised EPS (Q1-Q3 Avg × 4)₹18.08
- Book Value / Share₹322
- Price to Book3.50x
- ROCE1.20%
- ROE0.78%
- Sales Growth (TTM)+29%
Flash Summary: Tatva Chintan just posted Q3 FY26 revenue of ₹131 crore, up 52.9% YoY. Profit jumped 10,736% (from ₹0.06 crore loss year ago to ₹15.2 crore profit). The stock is down 17.7% in three months because investors still don’t believe the recovery is real. But management just detailed how a new manufacturing plant goes live next month (Dahej), how another ₹250 crore greenfield breaks ground next (Jolva), and how Euro 7 emissions are about to become the structural tailwind everyone ignored. TL;DR: The company isn’t dead. The market just moved faster than the reality.
02 — Introduction
The Specialty Chemical That Went From ₹45 Cr to ₹6 Cr PAT. And Then… Nobody Watched It Come Back.
Let’s rewind to March 2023. Tatva Chintan reported PAT of ₹45 crore. It was the hero stock. Then China said “nahin bhai, we’re using LNG trucks now,” and stopped buying Structure Directing Agents (SDA) — Tatva’s crown jewel product. Revenue fell. Margins collapsed. By March 2025, PAT was ₹6 crore. The stock got cut in half. CRISIL downgraded the credit ratings. And the market basically wrote this company off as “yet another Indian chemical company that got geopolitically destroyed.”
Then Q3 FY26 happened. Revenue grew 52.9% YoY. EBITDA margin was 19.5% (up from 8% in Q3 FY25). Management went on a concall and explained exactly why this turnaround was structural, not temporary. And the market… did nothing. The stock stayed down because investors were still processing the trauma of 2023-2025.
This is the kind of moment that separates the investors who do homework from those who just check IndiaBulls headlines.
03 — Business Model: WTF Do They Even Make?
Specialty Chemicals For People You Never Heard Of. For Industries You Never Think About.
Tatva Chintan makes four categories of specialty chemicals. Not commodities. Specialties. Which means: patented processes, high margins, niche customers, and if your process is good, customers can’t just switch suppliers on a Tuesday afternoon.
1. Structure Directing Agents (SDA) — 33% of H1 FY25 revenue: These are used to make zeolites, which are catalysts for petroleum and automotive emissions control. Tatva is the 2nd largest SDA manufacturer globally. They were the hero product until China said “we’re done.” But here’s the thing nobody paid attention to: Euro 7 emissions standards are coming to Europe and eventually globally. Euro 7 requires MORE catalyst loading per vehicle (even if fewer vehicles are made). It’s a 6-7 year structural tailwind starting 2027.
2. Phase Transfer Catalysts (PTC) — 30% of H1 FY25 revenue: India’s leading producer. These speed up chemical reactions in pharma API manufacturing. Boring but recurring.
3. Pharma & Agro Intermediates (PASC) — 35% of H1 FY25 revenue: The growth bet. Management is commercializing 6 new intermediates, including import-substitute agro chemicals. If even half succeed, this segment could double in 2-3 years.
4. Electrolyte Salts & Others — 2% of H1 FY25 revenue: For supercapacitor batteries. India’s largest producer. Growing but still tiny.
The business model is simple: take crude oil derivatives, process them through proprietary continuous-flow reactors and catalytic chemistry, and sell the output to pharma and agrochemical companies (71% exports globally). Margins are 14-26% depending on pricing. Execution capacity utilization is rising from 35% to 55% currently, which means margin expansion is mechanical as fixed costs get absorbed.
04 — Financials Overview
Q3 FY26: From Death to Recovery in 90 Days
Result type: Quarterly Results | Q3 FY26 EPS: ₹6.49 | Avg Q1–Q3 EPS: (₹2.84+₹4.24+₹6.49)/3 = ₹4.52 | Annualised EPS: ₹18.08
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 131 | 86 | 124 | +52.9% | +5.6% |
| Operating Profit | 25 | 7 | 22 | +257% | +13.6% |
| OPM % | 19% | 8% | 18% | +1100 bps | +100 bps |
| PAT | 15.2 | 0.06 | 10 | +25,233% | +52% |
| EPS (₹) | 6.49 | 0.06 | 4.24 | +10,750% | +53% |
What Just Happened: YoY comparison is bonkers (25,000%+) because the denominator was basically “we forgot to make money last year.” Ignore the absolute %. Focus on the trend: Q1 EPS ₹2.84 → Q2 ₹4.24 → Q3 ₹6.49. Sequential acceleration. Operating margin improved from 8% to 19% in one year. That’s a 1,100 basis point swing. In specialty chemicals, that’s… not normal. That’s evidence of structural recovery.
💬 Operating margins jump 1,100 bps in one year. Is that capacity utilization recovery or actual pricing improvement? Or both? What’s your hypothesis?
05 — Valuation: Fair Value Range
Can You Justify ₹1,128 for a Turnaround Stock?
Method 1: P/E Based
TTM EPS = ₹14.01. For a specialty chemicals turnaround (ROCE improving from 1.2% toward 8-10%), justified P/E = 35-50x during recovery phase.
→ 35x × ₹14.01 = ₹490.35 50x × ₹14.01 = ₹700.50
Range: ₹490 – ₹700
Method 2: Price to Book Value
Book Value = ₹322. For turnarounds with rising profitability, 1.4-1.8x P/BV is reasonable.
→ 1.4x × ₹322 = ₹450.8 1.8x × ₹322 = ₹579.6
Range: ₹450 – ₹580
Method 3: EV/EBITDA
TTM EBITDA ≈ ₹74 Cr. Enterprise Value with negligible debt ≈ ₹2,550 Cr. EV/EBITDA ≈ 34.5x. For specialty chemicals, 12-18x is normal. Current valuation is stretched for current profitability, but reasonable for projected FY26-FY27 normalized state.
At 15x EBITDA on projected ₹90-100 Cr FY26E EBITDA = ₹1,350-1,500 Cr EV, per share ₹575-640.
Range: ₹575 – ₹640
Consolidated View: Fair value range is ₹450-700 depending on execution assumptions. Current price ₹1,128 is above even bull-case scenarios. The stock is pricing in near-perfect execution of new manufacturing plants AND new product commercialization AND sustained margin expansion — all in next 12 months. That’s ambitious. Realistic price target on normalized FY27 earnings would be ₹550-650.
⚠️ EduInvesting Fair Value Range: ₹450 – ₹650. This range is for educational purposes only and not investment advice. Consult a SEBI-registered advisor before deciding.
06 — What’s Cooking: News, Triggers & Drama
Dahej Goes Live Next Month. Jolva Breaks Ground Next Month. And Management Is Acting Like It’s No Big Deal.
